ID: ALA3593817

Max Phase: Preclinical

Molecular Formula: C20H27N3O5S

Molecular Weight: 421.52

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCOc1cc(NS(C)(=O)=O)c(OCC)cc1CNC(=O)Nc1ccc(C)cc1

Standard InChI:  InChI=1S/C20H27N3O5S/c1-5-27-18-12-17(23-29(4,25)26)19(28-6-2)11-15(18)13-21-20(24)22-16-9-7-14(3)8-10-16/h7-12,23H,5-6,13H2,1-4H3,(H2,21,22,24)

Standard InChI Key:  ADBBUKZUEBEVEK-UHFFFAOYSA-N

Associated Targets(Human)

Receptor-type tyrosine-protein phosphatase F (LAR) 718 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Protein-tyrosine phosphatase 2C 2297 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Protein-tyrosine phosphatase 1C 687 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

T-cell protein-tyrosine phosphatase 1317 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Protein-tyrosine phosphatase 1B 8528 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 421.52Molecular Weight (Monoisotopic): 421.1671AlogP: 3.49#Rotatable Bonds: 9
Polar Surface Area: 105.76Molecular Species: NEUTRALHBA: 5HBD: 3
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 7.29CX Basic pKa: CX LogP: 2.11CX LogD: 1.81
Aromatic Rings: 2Heavy Atoms: 29QED Weighted: 0.57Np Likeness Score: -1.72

References

1. Du Y, Ling H, Zhang M, Shen J, Li Q..  (2015)  Discovery of novel, potent, selective and cellular active ADC type PTP1B inhibitors via fragment-docking-oriented de novel design.,  23  (15): [PMID:26100442] [10.1016/j.bmc.2015.05.032]

Source